Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Price Target from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have received a consensus rating of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $25.67.

A number of research firms recently commented on ATXS. Oppenheimer lifted their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. JMP Securities started coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price target on the stock. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Thursday, January 23rd.

Astria Therapeutics Stock Down 2.3 %

NASDAQ ATXS opened at $6.84 on Friday. Astria Therapeutics has a twelve month low of $6.64 and a twelve month high of $16.90. The company has a market cap of $385.98 million, a price-to-earnings ratio of -3.27 and a beta of 0.67. The business’s fifty day moving average is $8.50 and its 200 day moving average is $10.22.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ATXS. FMR LLC raised its position in shares of Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after purchasing an additional 1,767,714 shares during the period. RA Capital Management L.P. raised its holdings in Astria Therapeutics by 1.2% during the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after buying an additional 61,457 shares during the last quarter. Vestal Point Capital LP raised its holdings in shares of Astria Therapeutics by 23.1% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after acquiring an additional 750,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Astria Therapeutics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company’s stock worth $23,936,000 after acquiring an additional 41,833 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Astria Therapeutics by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 322,576 shares of the biotechnology company’s stock worth $2,884,000 after acquiring an additional 8,311 shares during the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.